# Coherence Neuro

> Coherence Neuro is a San Francisco medical-device company building closed-loop neurotechnology to treat cancer as a continuously monitored condition rather than a reactive battle. Founded in 2022 by University of Cambridge researchers Ben Woodington and Elise Jenkins, the company decodes the body's electrical signals in real time and delivers adaptive, AI-tuned stimulation through its flagship SOMA system - a wireless implant, wearable, and mobile app working together. Backed by a $10M seed round led by Artesian and Topology Ventures, Coherence aims to begin first-in-human trials in 2026.

- **Founded:** 2022
- **Headquarters:** San Francisco, United States
- **Founders:** Ben Woodington (Co-Founder & CEO), Elise Jenkins (Co-Founder)
- **Team size:** 26 employees
- **Products:** SOMA, Digital neural interfaces, AI-enabled data backend
- **Notable:** Closed a $10M seed round in November 2025 co-led by Artesian and Topology Ventures, Raised $13.46M in total funding to date, Developed SOMA, a closed-loop implant-wearable-app system for cancer management

## Products & services

- **SOMA** — The flagship closed-loop cancer-management system combining a wireless implant, a wearable device, and a mobile application to provide continuous patient monitoring and custom bioelectronic stimulation. Designed to bring cancer into stasis while improving patient quality of life; the first in a planned suite of cancer-management devices.
- **Digital neural interfaces** — Patented brain-computer interfaces that decode the body's electrical signals in real time and deliver adaptive, precisely tuned stimulation to modulate biological activity.
- **AI-enabled data backend** — A machine-learning system that learns and improves as more devices are deployed, turning each patient's data into better stimulation strategies across the network.

## Achievements

- Closed a $10M seed round in November 2025 co-led by Artesian and Topology Ventures
- Raised $13.46M in total funding to date
- Developed SOMA, a closed-loop implant-wearable-app system for cancer management
- On track to begin first-in-human trials in 2026
- Holds patents on digital neural interface technology

## Latest updates

- **2025-11** — Raised $10M seed round co-led by Artesian and Topology Ventures to advance its closed-loop neurotechnology for cancer treatment.
- **2026** — Preparing to begin first-in-human trials of the SOMA system.

## Links

- Website: https://coherenceneuro.com
- LinkedIn: http://www.linkedin.com/company/coherenceneuro
- Twitter/X: https://x.com/coherenceneuro

---

Profile page: https://yespress.io/coherence-neuro
Published by YesPress — https://yespress.io
Last updated: 2026-07-06